{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T11:26:09Z","timestamp":1794309969293,"version":"4.9.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To develop a novel model for preoperatively predicting the indication for adjuvant radiation therapy after radical prostatectomy according to current guideline recommendations of the European Association of Urology (EAU) based on patient and clinical tumor characteristics in high-risk prostate cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Within a high-volume center database (01\/2010-08\/2024), we identified high-risk prostate cancer patients. Univariable logistic regression models addressed indication for adjuvant radiation therapy. Multivariable logistic regression models included the most informative, statistically significant preoperative predictors. Harrell\u2019s concordance index (c-index) quantified accuracy after 2000 bootstrap resamples for internal validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 5691 patients, 2137 (38%) had indication for adjuvant radiation therapy according to current EAU guidelines (2025). Indication for adjuvant radiation therapy was associated with higher prostate volume (&gt;\u200945\u2009cm\n                      <jats:sup>3<\/jats:sup>\n                      and 25\u201345\u2009cm\n                      <jats:sup>3<\/jats:sup>\n                      ) and advanced tumor characteristics, namely higher prostate-specific antigen value (&gt;20\u2009ng\/ml and 10-20\u2009ng\/ml), advanced clinical tumor stage (cT3\/4 and cT2), lower number of sampled biopsy cores (\u2264\u200912), higher proportion of positive cores (continuous), and higher Gleason Grade Group in biopsy (5, 4, and 3). No association was observed for age and body-mass index and indication for adjuvant radiation therapy. Multivariable model c-index for the prediction of the indication for adjuvant radiation therapy was 0.761 (95% confidence interval 0.749\u20130.776).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Clinical tumor characteristics can be used for preoperatively predicting the indication for adjuvant radiation therapy after radical prostatectomy according to current EAU guideline recommendations in high-risk prostate cancer patients. Prior to clinical application, the present multivariable model should be externally validated within an independent cohort.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41391-025-01018-y","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T02:16:24Z","timestamp":1756865784000},"page":"353-359","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predicting the indication for adjuvant radiation therapy according to EAU guidelines among patients with high-risk prostate cancer: a novel multivariable model"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5460-4171","authenticated-orcid":false,"given":"Carolin","family":"Siech","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helge","family":"von Kriegstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Cano Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh Chi","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9237-3442","authenticated-orcid":false,"given":"Pierre","family":"Tennstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Preisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5660-7691","authenticated-orcid":false,"given":"Tobias","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Kriegmair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix K. H.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Graefen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7033-1380","authenticated-orcid":false,"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"1018_CR1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.5694\/mja2.51722","volume":"217","author":"IS Williams","year":"2022","unstructured":"Williams IS, McVey A, Perera S, O\u2019Brien JS, Kostos L, Chen K, et al. Modern paradigms for prostate cancer detection and management. Med J Aust. 2022;217:424\u201333. https:\/\/doi.org\/10.5694\/mja2.51722.","journal-title":"Med J Aust"},{"key":"1018_CR2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/JU.0000000000002250","volume":"207","author":"F Chierigo","year":"2022","unstructured":"Chierigo F, Wenzel M, Amling C, Flammia RS, Horlemann B, Zhe T, et al. Survival after radical prostatectomy versus radiation therapy in high-risk and very high-risk prostate cancer. J Urol. 2022;207:375\u201384. https:\/\/doi.org\/10.1097\/JU.0000000000002250.","journal-title":"J Urol"},{"key":"1018_CR3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/17512433.2018.1429265","volume":"11","author":"M Bandini","year":"2018","unstructured":"Bandini M, Fossati N, Gandaglia G, Preisser F, Dell\u2019Oglio P, Zaffuto E, et al. Neoadjuvant and adjuvant treatment in high-risk prostate cancer. Expert Rev Clin Pharm. 2018;11:425\u201338. https:\/\/doi.org\/10.1080\/17512433.2018.1429265.","journal-title":"Expert Rev Clin Pharm"},{"key":"1018_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.eururo.2017.01.039","volume":"72","author":"G Gandaglia","year":"2017","unstructured":"Gandaglia G, Briganti A, Clarke N, Karnes RJ, Graefen M, Ost P, et al. Adjuvant and salvage radiotherapy after radical prostatectomy in prostate cancer patients. Eur Urol. 2017;72:689\u2013709. https:\/\/doi.org\/10.1016\/j.eururo.2017.01.039.","journal-title":"Eur Urol"},{"key":"1018_CR5","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1200\/JCO.20.03714","volume":"39","author":"D Tilki","year":"2021","unstructured":"Tilki D, Chen M-H, Wu J, Huland H, Graefen M, Wiegel T, et al. Adjuvant versus early salvage radiation therapy for men at high risk for recurrence following radical prostatectomy for prostate cancer and the risk of death. J Clin Oncol. 2021;39:2284\u201393. https:\/\/doi.org\/10.1200\/JCO.20.03714.","journal-title":"J Clin Oncol"},{"key":"1018_CR6","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1200\/JCO.21.02800","volume":"40","author":"D Tilki","year":"2022","unstructured":"Tilki D, Chen M-H, Wu J, Huland H, Graefen M, D\u2019Amico AV. Adjuvant versus early salvage radiation therapy after radical prostatectomy for pN1 prostate cancer and the risk of death. J Clin Oncol. 2022;40:2186\u201392. https:\/\/doi.org\/10.1200\/JCO.21.02800.","journal-title":"J Clin Oncol"},{"key":"1018_CR7","unstructured":"Cornford P, Tilki D, van den Bergh RCN, Eberli D, De Meerleer G, De Santis M, et al. EAU - EANM - ESTRO - ESUR - ISUP. SIOG Guidelines on Prostate Cancer. 2025. https:\/\/uroweb.org\/guidelines\/prostate-cancer (accessed July 7, 2025)."},{"key":"1018_CR8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. part i: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86:148\u201363. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027.","journal-title":"Eur Urol"},{"key":"1018_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/JU.0000000000002758","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, et al. Clinically localized prostate cancer: AUA\/ASTRO guideline, part II: principles of active surveillance, principles of surgery, and follow-up. J Urol. 2022;208:19\u201325. https:\/\/doi.org\/10.1097\/JU.0000000000002758.","journal-title":"J Urol"},{"key":"1018_CR10","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Prostate Cancer. Version 2.2025. 2025."},{"key":"1018_CR11","doi-asserted-by":"publisher","unstructured":"Southall TM, Chung D, Nayak JG, Patel P. Impact of pre-treatment counselling on decisional regret of prostate cancer survivors: Cross-sectional analysis of patient-reported experience following diagnosis or treatment. Can Urol Assoc J. 2024;19. https:\/\/doi.org\/10.5489\/cuaj.8918.","DOI":"10.5489\/cuaj.8918"},{"key":"1018_CR12","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.urolonc.2011.02.005","volume":"31","author":"A Saini","year":"2013","unstructured":"Saini A, Berruti A, Cracco C, Sguazzotti E, Porpiglia F, Russo L, et al. Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy. Urol Oncol Semin Orig Investig. 2013;31:352\u20138. https:\/\/doi.org\/10.1016\/j.urolonc.2011.02.005.","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"1018_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/1754-9485.12508","volume":"61","author":"TP Shakespeare","year":"2017","unstructured":"Shakespeare TP, Chin S, Manuel L, Wen S, Hoffman M, Wilcox SW, et al. Long-term decision regret after post-prostatectomy image-guided intensity-modulated radiotherapy. J Med Imaging Radiat Oncol. 2017;61:141\u20135. https:\/\/doi.org\/10.1111\/1754-9485.12508.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"1018_CR14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","volume":"15","author":"FE Harrell Jr","year":"1996","unstructured":"Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361\u201387. https:\/\/doi.org\/10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4.","journal-title":"Stat Med"},{"key":"1018_CR15","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F","volume":"19","author":"JR Carpenter","year":"2000","unstructured":"Carpenter JR, Bithell JF. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med. 2000;19:1141\u201364. 9.","journal-title":"Stat Med"},{"key":"1018_CR16","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Lang Environ Stat Comput 2022. https:\/\/www.R-project.org\/ (accessed August 27, 2023)."},{"key":"1018_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11701-016-0627-3","volume":"11","author":"A Kumar","year":"2017","unstructured":"Kumar A, Samavedi S, Bates AS, Mouraviev V, Coelho RF, Rocco B, et al. Safety of selective nerve sparing in high risk prostate cancer during robot-assisted radical prostatectomy. J Robot Surg. 2017;11:129\u201338. https:\/\/doi.org\/10.1007\/s11701-016-0627-3.","journal-title":"J Robot Surg"},{"key":"1018_CR18","doi-asserted-by":"publisher","unstructured":"Siech C, Wenzel M, Knoblich G, Cano Garcia C, Humke C, Preisser F, et al. The association between the interval from biopsy to radical prostatectomy and biochemical recurrence in patients with intermediate- and high-risk prostate cancer. Front Oncol. 2025;14:01\u201308. https:\/\/doi.org\/10.3389\/fonc.2024.1533800.","DOI":"10.3389\/fonc.2024.1533800"},{"key":"1018_CR19","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.prnil.2024.07.002","volume":"12","author":"S Washino","year":"2024","unstructured":"Washino S, Kawase M, Shimbo M, Yamasaki T, Ohba K, Miki J, et al. Comparison of oncological outcomes between extended and no pelvic lymph node dissection in patients with high- or very high-risk prostate cancer: a multi-institutional study. Prostate Int. 2024;12:160\u20136. https:\/\/doi.org\/10.1016\/j.prnil.2024.07.002.","journal-title":"Prostate Int"},{"key":"1018_CR20","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.euo.2024.05.016","volume":"7","author":"D Milonas","year":"2024","unstructured":"Milonas D, Giesen A, Laenen A, Devos G, Briganti A, Gontero P, et al. Effect of radical prostatectomy on survival for men with high-risk nonmetastatic prostate cancer features selected according to STAMPEDE criteria: an EMPaCT study. Eur Urol Oncol. 2024;7:1478\u201386. https:\/\/doi.org\/10.1016\/j.euo.2024.05.016.","journal-title":"Eur Urol Oncol"},{"key":"1018_CR21","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","volume":"396","author":"CC Parker","year":"2020","unstructured":"Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet. 2020;396:1413\u201321. https:\/\/doi.org\/10.1016\/S0140-6736(20)31553-1.","journal-title":"Lancet"},{"key":"1018_CR22","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","volume":"21","author":"A Kneebone","year":"2020","unstructured":"Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol. 2020;21:1331\u201340. https:\/\/doi.org\/10.1016\/S1470-2045(20)30456-3.","journal-title":"Lancet Oncol"},{"key":"1018_CR23","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","volume":"21","author":"P Sargos","year":"2020","unstructured":"Sargos P, Chabaud S, Latorzeff I, Magn\u00e9 N, Benyoucef A, Supiot S, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020;21:1341\u201352. https:\/\/doi.org\/10.1016\/S1470-2045(20)30454-X.","journal-title":"Lancet Oncol"},{"key":"1018_CR24","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","volume":"396","author":"CL Vale","year":"2020","unstructured":"Vale CL, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet. 2020;396:1422\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(20)31952-8.","journal-title":"Lancet"},{"key":"1018_CR25","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1016\/j.clgc.2019.09.007","volume":"18","author":"S Knipper","year":"2020","unstructured":"Knipper S, Sadat-Khonsari M, Boehm K, Mandel P, Bud\u00e4us L, Steuber T, et al. Impact of adherence to multidisciplinary recommendations for adjuvant treatment in radical prostatectomy patients with high risk of recurrence. Clin Genitourin Cancer. 2020;18:e112\u201321. https:\/\/doi.org\/10.1016\/j.clgc.2019.09.007.","journal-title":"Clin Genitourin Cancer"},{"key":"1018_CR26","unstructured":"Memorial Sloan Kettering Cancer Center. Pre-Radical Prostatectomy Nomogram 2023. https:\/\/www.mskcc.org\/nomograms\/prostate\/pre_op (accessed July 7, 2025)."},{"key":"1018_CR27","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1097\/01.ju.0000091805.98960.13","volume":"170","author":"I Cagiannos","year":"2003","unstructured":"Cagiannos I, Karakiewcz PI, Eastham JA, Ohori M, Rabbani F, Gerigk C, et al. A Preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol. 2003;170:1798\u2013803. https:\/\/doi.org\/10.1097\/01.ju.0000091805.98960.13.","journal-title":"J Urol"},{"key":"1018_CR28","doi-asserted-by":"publisher","unstructured":"Siech C, Hoeh B, Rohlfsen E, Cano Garcia C, Humke C, K\u00f6llermann J, et al. Organ-confined pT2 ISUP4\/5 vs. nonorgan confined pT3\/4 ISUP2 vs. ISUP3 prostate cancer: differences in biochemical recurrence-free survival after radical prostatectomy. Urol Oncol Semin Orig Investig. 2024. https:\/\/doi.org\/10.1016\/j.urolonc.2024.07.008.","DOI":"10.1016\/j.urolonc.2024.07.008"},{"key":"1018_CR29","doi-asserted-by":"publisher","first-page":"830.e17","DOI":"10.1016\/j.urolonc.2021.04.031","volume":"39","author":"C W\u00fcrnschimmel","year":"2021","unstructured":"W\u00fcrnschimmel C, Wenzel M, Wang N, Tian Z, Karakiewicz PI, Graefen M, et al. Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center. Urol Oncol Semin Orig Investig. 2021;39:830.e17\u2013830.e26. https:\/\/doi.org\/10.1016\/j.urolonc.2021.04.031.","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"1018_CR30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2019.01.048","volume":"76","author":"F Preisser","year":"2019","unstructured":"Preisser F, Chun FKH, Pompe RS, Heinze A, Salomon G, Graefen M, et al. Persistent prostate-specific antigen after radical prostatectomy and its impact on oncologic outcomes. Eur Urol. 2019;76:106\u201314. https:\/\/doi.org\/10.1016\/j.eururo.2019.01.048.","journal-title":"Eur Urol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01018-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01018-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01018-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T02:43:02Z","timestamp":1779331382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01018-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1018"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-01018-y","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"assertion":[{"value":"1 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Approval by the local ethics committee has been obtained. Reporting follows the precepts established by the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All analyzed patients gave their informed written consent for data collection and analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"consent statement"}}]}}